1. Smolen JS, Aletaha D and Mcinnes IB: Rheumatoid arthritis.Lancet. 2016; 388(10055): 2023-38.
2. Silman AJ and Pearson JE: Epidemiology and genetics of rheumatoid arthritis.Arthritis Res. 2002; 4 Suppl 3: S265-72.
3. Faden G, Viapiana O, Fischetti F, Faganello G, Gatti D: Cardiovascular risk stratification and management of patients with rheumatoid arthritis in clinical practice: the "EPIDAURO registry".Int J Cardiol. 2014; 172(2): 534-6.
4. Erum U, Ahsan T and Khowaja D: Lipid abnormalities in patients with Rheumatoid Arthritis.Pak J Med Sci. 2017; 33(1): 227-230.
5. Ferraz-Amaro I, Gonzalez-Juanatey C, Lopez-Mejias R, Riancho-Zarrabeitia L and Gonzalez-Gay MA: Metabolic syndrome in rheumatoid arthritis.Mediators Inflamm. 2013; 2013: 710928.
6. Charles-Schoeman C, Fleischmann R, Davignon J, Schwartz H, Turner SM: Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib.Arthritis Rheumatol. 2015; 67(3): 616-25.
7. Choy E and Sattar N: Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions.Ann Rheum Dis. 2009; 68(4): 460-9.
8. Robertson J, Peters MJ, Mcinnes IB and Sattar N: Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm.Nat Rev Rheumatol. 2013; 9(9): 513-23.
9. Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD: Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease.Ann Rheum Dis. 2011; 70(3): 482-7.
10. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.Ann Rheum Dis. 2010; 69(9): 1580-8.
11. Jung YO and Kim HA: Recent paradigm shifts in the diagnosis and treatment of rheumatoid arthritis.Korean J Intern Med. 2012; 27(4): 378-87.
12. Karvounaris SA, Sidiropoulos PI, Papadakis JA, Spanakis EK, Bertsias GK: Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study.Ann Rheum Dis. 2007; 66(1): 28-33.
13. Galarza-Delgado DA, Azpiri-Lopez JR, Colunga-Pedraza IJ, Cardenas-De La Garza JA, Vera-Pineda R: Prevalence of comorbidities in Mexican mestizo patients with rheumatoid arthritis.Rheumatol Int. 20
14. Van Breukelen-Van Der Stoep DF, Van Zeben D, Klop B, Van De Geijn GJ, Janssen HJ: Marked underdiagnosis and undertreatment of hypertension and hypercholesterolaemia in rheumatoid arthritis.Rheumatology (Oxford). 2016; 55(7): 1210-6.
15. Nisar A, Rasheed U, Aziz W and Farooqi AZ: Prevalence of dyslipidemias in autoimmune rheumatic diseases.J Coll Physicians Surg Pak. 2012; 22(4): 235-9.
16. Attar SM: Hyperlipidemia in rheumatoid arthritis patients in Saudi Arabia. Correlation with C-reactive protein levels and disease activity.Saudi Med J. 2015; 36(6): 685-91.
17. Sheng X, Murphy MJ, Macdonald TM and Wei L: Effectiveness of statins on total cholesterol and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis.J Rheumatol. 2012; 39(1): 32-40.
18. Solomon DH, Reed GW, Kremer JM, Curtis JR, Farkouh ME: Disease activity in rheumatoid arthritis and the risk of cardiovascular events.Arthritis Rheumatol. 2015; 67(6): 1449-55.